GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biological Inc (SZSE:301047) » Definitions » EBIT

Sino Biological (SZSE:301047) EBIT : ¥253.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sino Biological EBIT?

Sino Biological's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥54.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥253.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sino Biological's annualized ROC % for the quarter that ended in Mar. 2024 was 4.86%. Sino Biological's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 21.65%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sino Biological's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.73%.


Sino Biological EBIT Historical Data

The historical data trend for Sino Biological's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biological EBIT Chart

Sino Biological Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 180.83 1,357.70 847.46 345.29 291.68

Sino Biological Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.01 63.38 80.51 54.78 54.60

Competitive Comparison of Sino Biological's EBIT

For the Biotechnology subindustry, Sino Biological's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biological's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biological's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sino Biological's EV-to-EBIT falls into.



Sino Biological EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥253.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biological  (SZSE:301047) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sino Biological's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=98.928 * ( 1 - 18.29% )/( (1662.669 + 1664.051)/ 2 )
=80.8340688/1663.36
=4.86 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6600.678 - 89.19 - ( 4848.819 - max(0, 136.378 - 5069.036+4848.819))
=1662.669

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6517.113 - 76.146 - ( 4776.916 - max(0, 121.489 - 5014.109+4776.916))
=1664.051

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sino Biological's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=218.384/( ( (900.896 + max(100.007, 0)) + (884.403 + max(132.221, 0)) )/ 2 )
=218.384/( ( 1000.903 + 1016.624 )/ 2 )
=218.384/1008.7635
=21.65 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(126.247 + 52.534 + 34.232) - (89.19 + 0 + 23.816)
=100.007

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(139.243 + 58.554 + 31.749) - (76.146 + 0 + 21.179)
=132.221

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sino Biological's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=253.26/4418.483
=5.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biological EBIT Related Terms

Thank you for viewing the detailed overview of Sino Biological's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biological (SZSE:301047) Business Description

Traded in Other Exchanges
N/A
Address
No. 18 Kechuang 10th Street, Room 306, Building 9, Beijing Economic and Technological Development Zon, Beijing, CHN, 100176
Sino Biological Inc is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.

Sino Biological (SZSE:301047) Headlines

No Headlines